Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Classifying oxidative stress by F2-isoprostane levels across human diseases: A meta-analysis.

van 't Erve TJ, Kadiiska MB, London SJ, Mason RP.

Redox Biol. 2017 Aug;12:582-599. doi: 10.1016/j.redox.2017.03.024. Epub 2017 Mar 28.

2.

TFP5 peptide, derived from CDK5-activating cofactor p35, provides neuroprotection in early-stage of adult ischemic stroke.

Ji YB, Zhuang PP, Ji Z, Wu YM, Gu Y, Gao XY, Pan SY, Hu YF.

Sci Rep. 2017 Jan 3;7:40013. doi: 10.1038/srep40013.

3.

Blockade of Apoptosis Signal-Regulating Kinase 1 Attenuates Matrix Metalloproteinase 9 Activity in Brain Endothelial Cells and the Subsequent Apoptosis in Neurons after Ischemic Injury.

Cheon SY, Cho KJ, Kim SY, Kam EH, Lee JE, Koo BN.

Front Cell Neurosci. 2016 Sep 2;10:213. doi: 10.3389/fncel.2016.00213. eCollection 2016.

4.

Malvidin's Effects on Rat Pial Microvascular Permeability Changes Due to Hypoperfusion and Reperfusion Injury.

Lapi D, Chiurazzi M, Di Maro M, Mastantuono T, Battiloro L, Sabatino L, Ricci S, Di Carlo A, Starita N, Guida B, Santillo M, Colantuoni A.

Front Cell Neurosci. 2016 Jun 30;10:153. doi: 10.3389/fncel.2016.00153. eCollection 2016.

5.

Association of oxidative stress with mortality: the Beaver Dam Eye Study.

Godreau A, Lee KE, Klein BE, Shankar A, Tsai MY, Klein R.

Oxid Antioxid Med Sci. 2012;1(3):161-167. Epub 2012 Dec 25.

6.

Cytochrome P450 and matrix metalloproteinase genetic modifiers of disease severity in Cerebral Cavernous Malformation type 1.

Choquet H, Trapani E, Goitre L, Trabalzini L, Akers A, Fontanella M, Hart BL, Morrison LA, Pawlikowska L, Kim H, Retta SF.

Free Radic Biol Med. 2016 Mar;92:100-9. doi: 10.1016/j.freeradbiomed.2016.01.008. Epub 2016 Jan 19.

7.

The Role of Oxidative Damage in the Pathogenesis and Progression of Alzheimer's Disease and Vascular Dementia.

Luca M, Luca A, Calandra C.

Oxid Med Cell Longev. 2015;2015:504678. doi: 10.1155/2015/504678. Epub 2015 Aug 2. Review.

8.

Matrix metalloproteinases as therapeutic targets for stroke.

Yang Y, Rosenberg GA.

Brain Res. 2015 Oct 14;1623:30-8. doi: 10.1016/j.brainres.2015.04.024. Epub 2015 Apr 25. Review.

9.

Targeting neutrophils in ischemic stroke: translational insights from experimental studies.

Jickling GC, Liu D, Ander BP, Stamova B, Zhan X, Sharp FR.

J Cereb Blood Flow Metab. 2015 Jun;35(6):888-901. doi: 10.1038/jcbfm.2015.45. Epub 2015 Mar 25. Review.

10.

The isoprostanes--25 years later.

Milne GL, Dai Q, Roberts LJ 2nd.

Biochim Biophys Acta. 2015 Apr;1851(4):433-45. doi: 10.1016/j.bbalip.2014.10.007. Epub 2014 Oct 30. Review.

11.

Hemorrhagic Transformation after Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke: Mechanisms, Models, and Biomarkers.

Wang W, Li M, Chen Q, Wang J.

Mol Neurobiol. 2015 Dec;52(3):1572-1579. doi: 10.1007/s12035-014-8952-x. Epub 2014 Nov 4. Review.

12.

Study of the correlations among some parameters of the oxidative status, gelatinases, and their inhibitors in a group of subjects with metabolic syndrome.

Hopps E, Lo Presti R, Montana M, Canino B, Averna MR, Caimi G.

Mediators Inflamm. 2014;2014:510619. doi: 10.1155/2014/510619. Epub 2014 Jul 10.

13.

Thioredoxin-interacting protein: a novel target for neuroprotection in experimental thromboembolic stroke in mice.

Ishrat T, Mohamed IN, Pillai B, Soliman S, Fouda AY, Ergul A, El-Remessy AB, Fagan SC.

Mol Neurobiol. 2015 Apr;51(2):766-78. doi: 10.1007/s12035-014-8766-x. Epub 2014 Jun 18. Erratum in: Mol Neurobiol. 2015 Apr;51(2):779-80.

14.

Antioxidant effects of statins in patients with atherosclerotic cerebrovascular disease.

Moon GJ, Kim SJ, Cho YH, Ryoo S, Bang OY.

J Clin Neurol. 2014 Apr;10(2):140-7. doi: 10.3988/jcn.2014.10.2.140. Epub 2014 Apr 23.

15.

Hemorrhagic transformation after ischemic stroke in animals and humans.

Jickling GC, Liu D, Stamova B, Ander BP, Zhan X, Lu A, Sharp FR.

J Cereb Blood Flow Metab. 2014 Feb;34(2):185-99. doi: 10.1038/jcbfm.2013.203. Epub 2013 Nov 27. Review.

16.

Mmp-9 inhibition: a therapeutic strategy in ischemic stroke.

Chaturvedi M, Kaczmarek L.

Mol Neurobiol. 2014 Feb;49(1):563-73. doi: 10.1007/s12035-013-8538-z. Epub 2013 Sep 12. Review.

17.

Enrichment of elevated plasma F2t-isoprostane levels in individuals with autism who are stratified by presence of gastrointestinal dysfunction.

Gorrindo P, Lane CJ, Lee EB, McLaughlin B, Levitt P.

PLoS One. 2013 Jul 3;8(7):e68444. doi: 10.1371/journal.pone.0068444. Print 2013.

18.

B Vitamins and Antioxidants Intake is Negatively Correlated with Risk of Stroke in Iran.

Hariri M, Maghsoudi Z, Darvishi L, Askari G, Hajishafiee M, Ghasemi S, Khorvash F, Iraj B, Ghiasvand R.

Int J Prev Med. 2013 May;4(Suppl 2):S284-9.

19.

SOD2 in mitochondrial dysfunction and neurodegeneration.

Flynn JM, Melov S.

Free Radic Biol Med. 2013 Sep;62:4-12. doi: 10.1016/j.freeradbiomed.2013.05.027. Epub 2013 May 29. Review.

20.

Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke.

Lakhan SE, Kirchgessner A, Tepper D, Leonard A.

Front Neurol. 2013 Apr 3;4:32. doi: 10.3389/fneur.2013.00032. eCollection 2013.

Supplemental Content

Support Center